Videos

Many researchers and oncologists anticipate a role for antiangiogenic strategies in future treatment paradigms; yet just what that role will be remains elusive.

An interview with Elaine R. Mardis, PhD, discussing the clinical applications of genomic research on the near horizon that will enable more personalized therapy for patients at earlier stages of breast cancer.

Julie R. Gralow, MD, from Seattle Cancer Care Alliance, discusses the side effects associated with the administration of zoledronic acid.

Does "think pink" actually raise awareness of breast cancer?

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses results from the phase III EMILIA trial that examined the T-DM1 for women with HER2-positive breast cancer.

Within the past two years, the oncology community has seen the FDA approve three practice-changing therapies for breast cancer and the progress of a promising fourth agent, T-DM1.

Updates on breast cancer risk factors, screening methods, and treatments for the nurse navigators who are guiding patients from diagnosis to treatment and, hopefully, through survivorship.

During the 11th International Congress on The Future of Breast Cancer, Hope Rugo, MD, offered a snapshot of the research community's progress in the study and treatment of the disease.

Combining tamoxifen with everolimus increased the clinical benefit rate, time to progression, and overall survival versus tamoxifen alone in postmenopausal women with metastatic breast cancer.

Long-term follow-up of the HERA trial confirms that 1 year of adjuvant therapy with trastuzumab should remain the standard of care for treatment of women with HER2-positive invasive early breast cancer.

Dr. Louis Weiner, from Lombardi Comprehensive Cancer Center, on the T-DM1 mechanism of action in HER2-positive breast cancer.

An updated analysis of the phase III EMILIA trial showed that T-DM1 significantly extended survival in women with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Agustin A. Garcia, MD, from Keck School of Medicine of USC, discusses clinical trials that investigated combination therapy for treating advanced breast cancer.

A new formulation of trastuzumab that is administered subcutaneously appears to be as effective as the approved bodyweight-based intravenous regimen in women with HER2-positive breast cancer.

Pathologist Dr. Elizabeth Hammond, from Intermountain Healthcare, Discusses the Ongoing ASCO/CAP HER2 Testing Guideline Revisions.

Updated results from the BOLERO-2 trial support the study's earlier findings that mTOR kinase inhibitor everolimus improves survival for postmenopausal patients with breast cancer.

In this interview, Lance A. Liotta, MD, PhD, discusses the hypothosis that led to the study and the research thus far into chloroquine.

Carrie Stricker from the Abramson Cancer Center of the University of Pennsylvania on the Efficacy of Survivorship Care Plans for Posttreatment Breast Cancer Survivors.

Patients with early-stage breast cancer at high risk of residual nodal disease might benefit from axillary lymph node dissection.

New data show that cancer-related fatigue is reported by only "a small minority" of women >6 months after completing adjuvant therapy for breast cancer.

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the mTOR Inhibitor Everolimus for HER2-Negative Breast Cancer.

Dr. Julie Gralow, from the Seattle Cancer Care Alliance, Discusses the Antibody Drug Conjugate T-DM1 for Breast Cancer.

Forty years after the declaration of war on cancer, one of the most profound shifts in cancer care today is a new focus on treating those living beyond cancer, as well as those living with cancer.

Dr. Hope Rugo, from the UCSF Helen Diller Family Comprehensive Cancer Center, Examines Angiogenesis Inhibition Trials in Advanced Breast Cancer.

Genentech is seeking the FDA's approval to offer T-DM1 for patients with HER2-positive metastatic breast cancer amid updated results from the pivotal EMILIA trial showing significantly improved OS.

Dr. Louis Weiner, from the Lombardi Comprehensive Cancer Center, Discusses the T-DM1 EMILIA Trial for HER2-Positive Breast Cancer.

A "substantial minority" of radiation oncologists report that surgeons fail to include them in the breast cancer treatment decision-making process before definitive surgery.

Elaine Mardis, from the Genome Institute at Washington University School of Medicine, on Sensitivity to Aromatase Inhibitors

Researchers found that when anastrozole and fulvestrant are given in combination that patients with metastatic breast cancer experienced longer periods of PFS and OS.

Melinda L. Telli, MD, is actively involved in clinical research that focuses on DNA repair targeted therapeutics for the treatment of triple-negative and BRCA1/2 mutation-associated breast cancer.